Literature DB >> 19494254

New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting.

Andrew D Wells1.   

Abstract

The vertebrate immune system has evolved to deal with invasive pathogens, but this adaptation comes at the expense of immunopathology. Among a number of mechanisms that coevolved to control adaptive immunity is anergy, the functional inactivation of T lymphocytes that respond to Ag in the absence of inflammation. In this review, I highlight a series of intracellular proteins in quiescent T cells that function to integrate signals from Ag, costimulatory, and growth factor receptors. These factors ensure that cells that fail to engage all three pathways are shunted into an alternative transcriptional program designed to dissuade them from participating in subsequent immune responses. Recent studies indicate that anergy is the combined result of factors that negatively regulate proximal TCR-coupled signal transduction, together with a program of active transcriptional silencing that is reinforced through epigenetic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494254     DOI: 10.4049/jimmunol.0803917

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  76 in total

1.  IL-2 and IL-4 stimulate MEK1 expression and contribute to T cell resistance against suppression by TGF-beta and IL-10 in asthma.

Authors:  Qiaoling Liang; Lei Guo; Shaila Gogate; Zunayet Karim; Arezoo Hanifi; Donald Y Leung; Magdalena M Gorska; Rafeul Alam
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

Review 2.  Peli: a family of signal-responsive E3 ubiquitin ligases mediating TLR signaling and T-cell tolerance.

Authors:  Wei Jin; Mikyoung Chang; Shao-Cong Sun
Journal:  Cell Mol Immunol       Date:  2012-02-06       Impact factor: 11.530

Review 3.  Epigenetic mechanisms in inflammation.

Authors:  D Bayarsaihan
Journal:  J Dent Res       Date:  2011-01       Impact factor: 6.116

4.  Changing the energy of an immune response.

Authors:  Meghan M Delmastro-Greenwood; Jon D Piganelli
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

5.  Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8α⁺ semi-invariant T cells.

Authors:  Cameron J Turtle; Jeff Delrow; Rochelle C Joslyn; Hillary M Swanson; Ryan Basom; Laura Tabellini; Colleen Delaney; Shelly Heimfeld; John A Hansen; Stanley R Riddell
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

Review 6.  New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation.

Authors:  Andrew D Wells; Peter A Morawski
Journal:  Nat Rev Immunol       Date:  2014-03-07       Impact factor: 53.106

7.  T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.

Authors:  Fabienne Lucas; Michael Pennell; Ying Huang; Don M Benson; Yvonne A Efebera; Maria Chaudhry; Tiffany Hughes; Jennifer A Woyach; John C Byrd; Suohui Zhang; Desiree Jones; Xiangnan Guan; Christin E Burd; Ashley E Rosko
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-21       Impact factor: 5.742

Review 8.  Induction and stability of the anergic phenotype in T cells.

Authors:  Rut Valdor; Fernando Macian
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

9.  Balance between NF-κB p100 and p52 regulates T cell costimulation dependence.

Authors:  Maria Letizia Giardino Torchia; Dietrich B Conze; Dragana Jankovic; Jonathan D Ashwell
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

10.  Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.

Authors:  Omar Eton; Merrick I Ross; Mary Jo East; Paul F Mansfield; Nicholas Papadopoulos; Julie A Ellerhorst; Agop Y Bedikian; Jeffrey E Lee
Journal:  J Transl Med       Date:  2010-01-29       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.